•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Ademi LLP is investigating Organon (NYSE: OGN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sun Pharma. Organon stockholders will receive $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion. Organon insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Organon by imposing a significant penalty if Organon accepts a competing bid. We are investigating the conduct of the Organon board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Ademi LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
